Stock comparison
Elanco Animal Health
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ELAN
Elanco Animal Health
Market cap
$10.85B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ELAN | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 32F | 79B | HALO |
| Benjamin Graham | 31F | 83A | HALO |
| Philip Fisher | 30F | 65B | HALO |
| Peter Lynch | 6F | 53D | HALO |
| Joel Greenblatt | 40D | 40D | Tie |
| Charlie Munger | 32F | 80C | HALO |
| Terry Smith | 23F | 84A | HALO |
Side-by-side metrics
| Metric | ELAN | HALO |
|---|---|---|
| Market cap | $10.85B | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | 53.5x | 10.2x |
| ROIC (TTM) | 3.77% | 23.65% |
| Gross margin | 49.44% | 81.24% |
| Net margin | -4.95% | 23.13% |
| Revenue CAGR 5y | -0.26% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.6x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ELAN leads on
- P/E (TTM)-vs 24.0x+159%
- Debt / Equity0.6xvs 1.0x+35%
- Market cap$10.85Bvs $8.1B+25%
HALO leads on
- Net margin23.13%vs -4.95%+121%
- Revenue CAGR 5y33.23%vs -0.26%+101%
- ROIC (TTM)23.65%vs 3.77%+84%
- EV/EBIT10.2xvs 53.5x+81%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.